FLT3 and myelodysplastic syndrome: Wang et al. [21], studying patients with NPM1 mutation/FLT3-ITD mutation and with NPM1 mutation/MDS-related mutations, reported no difference in PFS and OS between those who received allo-SCT and those who did not.